PubMed Health⌕ Search

PubMed · 11285719

Are we treating to target?

Abstract

The identification of a number of independent risk factors for coronary heart disease (CHD) led to the development of guidelines for the prevention of CHD in an attempt to target these risk factors and reduce the rates of CHD-related morbidity and mortality. Surveys conducted of physician's clinical practice patterns indicate, however, that the recommendations made in the guidelines are often not implemented and the predefined goals of therapy for patients are not achieved. Possible reasons for this apparent shortfall in preventive care include a lack of physician awareness of evidenced-based guidelines, an insufficient focus towards preventive care in health care systems, and patient non-compliance with lifestyle changes and medication. To ensure an optimal outcome, specialists, primary care physicians and the patient need to provide an integrated approach to the management of CHD. The first step is to achieve universal understanding and implementation of the guidelines. Not only do guidelines promote interventions of proven benefit, but when followed they also improve consistency of care. Nurse-led shared-care programs, which individualize care based on a comprehensive assessment of CHD risk factors, are of proven benefit and offer continuity between the hospital and a patients return to the community. Patients themselves also have a role to play in the management of their disease by adhering to lifestyle changes and medication.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Erhardt. 2000. Are we treating to target?. https://doi.org/10.1016/s0021-9150(00)00562-1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗